The American Diabetes Association 2021 Scientific Sessions run from June 25 to 29. This short slide show highlights 6 clinical trial updates that are a "must see" for primary care clinicians.
The American Diabetes Association Virtual 81st Scientific Sessions kick off on Friday, June 25 and run through Tuesday, June 29, 2021.
The topics to be covered this year include many focused on the impact of COVID-19 on persons with diabetes and on their care. There are hundreds of poster presentations and updates on both ongoing and published clinical trial programs studying drug classes that might once have targeted only hyperglycemia but now are proving effective in cardiovascular and renal disease.
The following slides provide a brief look at 6 clinical trial updates our editors think will be of particular interest to clinicians in primary care. (Note: All times are EST)
SURPASS Trials – Tirzepatide.
Julio Rosenstock, MD, Director of the Dallas Diabetes Research Center at Medical City and Principal Investigator for SURPASS-1.
Next Chapter in Incretin-Based Therapies—Tirzepatide, a Novel Dual GIP/GLP-1 Receptor Agonist—Results from the First Phase 3 SURPASS Clinical Trials. Tuesday, June 29th. More details.
AMPLITUDE-O – Efpeglenatide
Hertzel C. Gerstein, MD, MSc, FRCPC, Professor of Medicine and Population Health Institute Chair in Diabetes Research at McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada, Principal Investigator.
First Results of the Effect of Efpeglenatide on Cardiovascular Outcomes (AMPLITUDE-O) Trial. Monday, June 28th, 2:15 – 4:15. More details.
SCORED & SOLOIST – Sotagliflozin
Deepak Bhatt, MD, MPH, Executive Director of Interventional Cardiovascular Programs at Brigham and Women’s Hospital Heart & Vascular Center and Professor of Medicine at Harvard Medical School, Lead Author, SCORED.
Update on SCORED and SOLOIST Cardiovascular and Kidney Outcomes Trials. Tuesday, June 29th, 10:15 – 12:15. More details.
DARE-19 Dapagliflozin in COVID-19
Mikhail Kosiborod, MD, Vice President of Research at Saint Luke’s Health System and Executive Director of Cardiometabolic Center Alliance, Principal Investigator.
Efficacy and Safety of Dapagliflozin in Patients with and without Type 2 Diabetes Hospitalized with COVID-19—Results from the DARE-19 Global Randomized Controlled Trial. Sunday, June 27th, 2:15 – 3:15. More details.
GRADE Study – comparison of 4 commonly used T2D agents
David Nathan, MD, Director, Massachusetts General Hospital Diabetes Center and Clinical Research Center, Professor of Medicine, Harvard Medical School, Principal Investigator.
Results of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study, Monday, June 28th, 4:30 – 6:55. More details.